GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Celyad Oncology SA (OTCPK:CYADY) » Definitions » Gross-Profit-to-Asset %

Celyad Oncology (Celyad Oncology) Gross-Profit-to-Asset % : 0.00% (As of Jun. 2023)


View and export this data going back to 2015. Start your Free Trial

What is Celyad Oncology Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. Celyad Oncology's annualized Gross Profit for the quarter that ended in Jun. 2023 was $0.00 Mil. Celyad Oncology's average Total Assets over the quarter that ended in Jun. 2023 was $17.04 Mil. Therefore, Celyad Oncology's annualized Gross-Profit-to-Asset % for the quarter that ended in Jun. 2023 was 0.00%.


Celyad Oncology Gross-Profit-to-Asset % Historical Data

The historical data trend for Celyad Oncology's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Celyad Oncology Gross-Profit-to-Asset % Chart

Celyad Oncology Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Gross-Profit-to-Asset %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.56 0.01 0.01 - -

Celyad Oncology Quarterly Data
Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Dec22 Jun23
Gross-Profit-to-Asset % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Celyad Oncology's Gross-Profit-to-Asset %

For the Biotechnology subindustry, Celyad Oncology's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Celyad Oncology's Gross-Profit-to-Asset % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Celyad Oncology's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where Celyad Oncology's Gross-Profit-to-Asset % falls into.



Celyad Oncology Gross-Profit-to-Asset % Calculation

Celyad Oncology's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Dec. 2022 is calculated as:

Gross-Profit-to-Asset %=Gross Profit (A: Dec. 2022 )/( (Total Assets (A: Dec. 2021 )+Total Assets (A: Dec. 2022 ))/ count )
=0/( (90.331+20.886)/ 2 )
=0/55.6085
=0.00 %

Celyad Oncology's annualized Gross-Profit-to-Asset % for the quarter that ended in Jun. 2023 is calculated as:

Gross-Profit-to-Asset %=Gross Profit (Q: Jun. 2023 )/( (Total Assets (Q: Dec. 2022 )+Total Assets (Q: Jun. 2023 ))/ count )
=0/( (20.886+13.194)/ 2 )
=0/17.04
=0.00 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is four times the quarterly (Jun. 2023) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.


Celyad Oncology Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of Celyad Oncology's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.


Celyad Oncology (Celyad Oncology) Business Description

Traded in Other Exchanges
Address
Rue Edouard Belin 2, Axis Business Park, Brabant Wallon, Mont-Saint-Guibert, BEL, 1435
Celyad Oncology SA is a biopharmaceutical company focused on the discovery and development of innovative technologies for chimeric antigen receptor T-cell (CAR T) therapies. The company focuses on solid tumors and hematological malignancies. The firm has CYAD-01 and CYAD-02 programs in the pipeline. The company owns trademarks and service marks including CELYAD, C-CATH, C_CURE, CAR-T Cell, THINK, CYAD01 - Deplethink, CYAD02 - Cycle1, CwalityCAR, CYAD-101, and new engagers. The firm has Cardiology and Immuno-oncology operating segments.